摘要：Patients who undergo multiple-day chemotherapy sessions experience hard-to-treat nausea and vomiting. Currently, there is no effective standard treatment for this condition. This study compared the preventive effect of first-generation 5-hydroxytryptamine 3 receptor antagonists (5-HT 3 RAs) and second-generation 5-HT 3 RAs palonosetron in multiple-day chemotherapy-induced nausea and vomiting. The design of this study was a retrospective case-control study of patients who received a five-day cisplatin-based chemotherapy and were treated with aprepitant, dexamethasone, granisetron, and ramosetron or palonosetron. The patients were divided into two groups: patients given granisetron and ramosetron (the first-generation group), and those given palonosetron (palonosetron group). The percentage of patients with a complete response or total control was assessed. They were divided into three phases: 0–216 h (overall phase), 0–120 h (remedial phase), and 120–216 h (after phase). The remedial phase was further divided into 0–24 h (early phase) and 24–120 h (later phase). Moreover, the nutritional status of each patient was assessed by noting the patients’ total calorie-intake per day and total parenteral nutrition. First-generation 5-HT 3 RAs and palonosetron were used for treatment in 18 and 28 patients, respectively. The complete response rate and caloric oral intake of the later phase were higher in the palonosetron group than in the first-generation group. We conclude that palonosetron treatment was more effective than first-generation 5-HT 3 RAs in controlling multiple-day chemotherapy-induced nausea and vomiting.
关键词：palonosetron;chemotherapy-induced nausea and vomiting;supportive care;5-hydroxytryptamine 3 antagonist;multiple-day chemotherapy
